Home
Coronovirus
COVID-19 Blog
CDC Official Microsite (Covid-19)
COVID-19 Media items.
Respiratory Virus
SARS-CoV-2
Coronavirus
COVID-19
Mutation
New Variant
RSV
Influenza
Influenza 1918
Rhinovirus
SARS
Other Viruses
HMPV
HIV
Mumps
Rubulavirus
Ebola
Measles
The Team
About
Resources
WorkPlacewellness.life
Contact Us
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
VIROLOGYCONSULT.COM
Home
Coronovirus
COVID-19 Blog
CDC Official Microsite (Covid-19)
COVID-19 Media items.
Respiratory Virus
All
SARS-CoV-2
Coronavirus
COVID-19
Mutation
New Variant
RSV
Influenza
Influenza 1918
Rhinovirus
SARS
More Evidence of Protective Immunity After COVID-19, NEJM Journal Watch:
SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals |…
Full length article OUTBREAK of novel corona virus disease (COVID-19): Antecedence…
Phase 3 trial for Moderna COVID-19 vaccine begins amid US summer…
Other Viruses
All
HMPV
HIV
Mumps
Rubulavirus
Ebola
Measles
COVID-19 in a Patient With HIV Infection
Polio, measles, other diseases set to surge as COVID-19 forces suspension…
PrEP: Preventative HIV drug available in England from April
Articles Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind,…
The Team
About
Resources
WorkPlacewellness.life
Contact Us
Home
Clinical Trial
Clinical Trial
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review
Rob LW
-
22nd July 2020
U.K. megatrial outshines other drug studies
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet
One U.K. trial is transforming COVID-19 treatment. Why haven’t others delivered more results?
Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional...
Rob LW
-
13th June 2020
0
A Trial of Lopinavir–Ritonavir in Covid-19
Rob LW
-
8th May 2020
0
Against pandemic research exceptionalism
Rob LW
-
1st May 2020
0
Coronovirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt
Rob LW
-
11th April 2020
0
Open Orphan PLC Q&A: Coronavirus challenge study model (LON:ORPH)
Rob LW
-
27th March 2020
0
A phase IIb study to determine the safety and efficacy of...
Rob LW
-
26th February 2020
0
Effects of influenza vaccination on seasonal influenza symptoms: A prospective observational...
Rob LW
-
26th February 2020
0
GRDG Sciences Announces Successful Antiviral Testing of Equivir Preparations Underway for...
Rob LW
-
26th February 2020
0
We have daily and weekly curated newsletters.
Just click above to choose your options.
